Lv22
140 积分 2026-01-28 加入
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma
1小时前
已完结
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial
1小时前
已完结
CT radiomics to predict pathologic complete response after neoadjuvant immunotherapy plus chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
7个月前
已完结
皖公网安备34019202002308
